APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Phosphoinositide 3-Kinase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Phosphoinositide 3-Kinase Inhibitor Market Outlook and Growth Opportunities 2026

Report ID 174025540430 December 2025198 pages

Choose your research edition.

Industry ResearchPhosphoinositide 3-Kinase Inhibitor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphoinositide 3-Kinase Inhibitor Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Phosphoinositide 3-Kinase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphoinositide 3-Kinase Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphoinositide 3-Kinase Inhibitor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Phosphoinositide 3-Kinase Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Phosphoinositide 3-Kinase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phosphoinositide 3-Kinase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phosphoinositide 3-Kinase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Phosphoinositide 3-Kinase Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Phosphoinositide 3-Kinase Inhibitor market include Gilead Sciences Inc., Secura Bio, Inc., TG Therapeutics Inc., Bayer AG and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Phosphoinositide 3-Kinase Inhibitor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phosphoinositide 3-Kinase Inhibitor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phosphoinositide 3-Kinase Inhibitor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Phosphoinositide 3-Kinase Inhibitor market.

Phosphoinositide 3-Kinase Inhibitor Segment by Company

Gilead Sciences Inc.

Secura Bio, Inc.

TG Therapeutics Inc.

Bayer AG

Novartis AG

Phosphoinositide 3-Kinase Inhibitor Segment by Type

Dual PI3K/mTOR inhibitors

Pan-PI3K Inhibitors

Other

Phosphoinositide 3-Kinase Inhibitor Segment by Application

FL - Follicular Iymphoma

CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma

Other Indications

Phosphoinositide 3-Kinase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Phosphoinositide 3-Kinase Inhibitor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Phosphoinositide 3-Kinase Inhibitor key companies, revenue, market share, and recent developments.

3. To split the Phosphoinositide 3-Kinase Inhibitor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Phosphoinositide 3-Kinase Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phosphoinositide 3-Kinase Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Phosphoinositide 3-Kinase Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphoinositide 3-Kinase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphoinositide 3-Kinase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphoinositide 3-Kinase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phosphoinositide 3-Kinase Inhibitor industry.

Chapter 3: Detailed analysis of Phosphoinositide 3-Kinase Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Phosphoinositide 3-Kinase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Phosphoinositide 3-Kinase Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phosphoinositide 3-Kinase Inhibitor Industry Trends Table 2. Phosphoinositide 3-Kinase Inhibitor Industry Drivers Table 3. Phosphoinositide 3-Kinase Inhibitor Industry Opportunities and Challenges Table 4. Phosphoinositide 3-Kinase Inhibitor Industry Restraints Table 5. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phosphoinositide 3-Kinase Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Phosphoinositide 3-Kinase Inhibitor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Phosphoinositide 3-Kinase Inhibitor Key Company Manufacturing Base & Headquarters Table 9. Global Phosphoinositide 3-Kinase Inhibitor Company, Product Type & Application Table 10. Global Phosphoinositide 3-Kinase Inhibitor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Phosphoinositide 3-Kinase Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Dual PI3K/mTOR inhibitors Table 15. Significant Companies of Pan-PI3K Inhibitors Table 16. Significant Companies of Other Table 17. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type (2021-2026) Table 21. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type (2027-2032) Table 22. Significant Companies of FL - Follicular Iymphoma Table 23. Significant Companies of CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma Table 24. Significant Companies of Other Indications Table 25. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application (2021-2026) Table 29. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application (2027-2032) Table 30. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Region (2021-2026) Table 33. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Region (2027-2032) Table 35. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Market Share by Country (2021-2026) Table 38. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Market Share by Country (2027-2032) Table 40. Gilead Sciences Inc. Company Information Table 41. Gilead Sciences Inc. Business Overview Table 42. Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 44. Gilead Sciences Inc. Recent Development Table 45. Secura Bio, Inc. Company Information Table 46. Secura Bio, Inc. Business Overview Table 47. Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 49. Secura Bio, Inc. Recent Development Table 50. TG Therapeutics Inc. Company Information Table 51. TG Therapeutics Inc. Business Overview Table 52. TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 54. TG Therapeutics Inc. Recent Development Table 55. Bayer AG Company Information Table 56. Bayer AG Business Overview Table 57. Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 59. Bayer AG Recent Development Table 60. Novartis AG Company Information Table 61. Novartis AG Business Overview Table 62. Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 64. Novartis AG Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Phosphoinositide 3-Kinase Inhibitor Product Image Figure 2. Global Phosphoinositide 3-Kinase Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphoinositide 3-Kinase Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Phosphoinositide 3-Kinase Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Dual PI3K/mTOR inhibitors Image Figure 8. Pan-PI3K Inhibitors Image Figure 9. Other Image Figure 10. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type (2021-2032) Figure 13. FL - Follicular Iymphoma Image Figure 14. CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma Image Figure 15. Other Indications Image Figure 16. Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application (2021-2032) Figure 19. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 22. North America Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 28. South America Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Dual PI3K/mTOR inhibitors
  • Pan-PI3K Inhibitors
  • Other
Applications
  • FL - Follicular Iymphoma
  • CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
  • Other Indications
Companies covered
  • Gilead Sciences Inc.
  • Secura Bio, Inc.
  • TG Therapeutics Inc.
  • Bayer AG
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phosphoinositide 3-Kinase Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phosphoinositide 3-Kinase Inhibitor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Phosphoinositide 3-Kinase Inhibitor Market Dynamics
  1. 2.1 Phosphoinositide 3-Kinase Inhibitor Industry Trends
  2. 2.2 Phosphoinositide 3-Kinase Inhibitor Industry Drivers
  3. 2.3 Phosphoinositide 3-Kinase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Phosphoinositide 3-Kinase Inhibitor Industry Restraints
3 Phosphoinositide 3-Kinase Inhibitor Market by Company
  1. 3.1 Global Phosphoinositide 3-Kinase Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Phosphoinositide 3-Kinase Inhibitor Company Ranking (2024-2026)
  4. 3.4 Global Phosphoinositide 3-Kinase Inhibitor Company Manufacturing Base and Headquarters
  5. 3.5 Global Phosphoinositide 3-Kinase Inhibitor Company Product Type and Application
  6. 3.6 Global Phosphoinositide 3-Kinase Inhibitor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Phosphoinositide 3-Kinase Inhibitor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Phosphoinositide 3-Kinase Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Phosphoinositide 3-Kinase Inhibitor Market by Type
  1. 4.1 Phosphoinositide 3-Kinase Inhibitor Type Introduction
  2. 4.1.1 Dual PI3K/mTOR inhibitors
  3. 4.1.2 Pan-PI3K Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type
  6. 4.2.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Type (2021-2032)
  8. 4.2.3 Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type (2021-2032)
5 Phosphoinositide 3-Kinase Inhibitor Market by Application
  1. 5.1 Phosphoinositide 3-Kinase Inhibitor Application Introduction
  2. 5.1.1 FL - Follicular Iymphoma
  3. 5.1.2 CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
  4. 5.1.3 Other Indications
  5. 5.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application
  6. 5.2.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Application (2021-2032)
  8. 5.2.3 Global Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application (2021-2032)
6 Phosphoinositide 3-Kinase Inhibitor Regional Value Analysis
  1. 6.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032)
  7. 6.3.2 North America Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032)
  10. 6.4.2 Europe Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032)
  16. 6.6.2 South America Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Phosphoinositide 3-Kinase Inhibitor Country-level Value Analysis
  1. 7.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Phosphoinositide 3-Kinase Inhibitor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Phosphoinositide 3-Kinase Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences Inc.
  2. 8.1.1 Gilead Sciences Inc. Company Information
  3. 8.1.2 Gilead Sciences Inc. Business Overview
  4. 8.1.3 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  6. 8.1.5 Gilead Sciences Inc. Recent Developments
  7. 8.2 Secura Bio, Inc.
  8. 8.2.1 Secura Bio, Inc. Company Information
  9. 8.2.2 Secura Bio, Inc. Business Overview
  10. 8.2.3 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  12. 8.2.5 Secura Bio, Inc. Recent Developments
  13. 8.3 TG Therapeutics Inc.
  14. 8.3.1 TG Therapeutics Inc. Company Information
  15. 8.3.2 TG Therapeutics Inc. Business Overview
  16. 8.3.3 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  18. 8.3.5 TG Therapeutics Inc. Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst